Glutamine antagonists may KEAP lung cancer in check

Eliot B. Blatt, Ralph J. DeBerardinis

Research output: Contribution to journalArticlepeer-review

Abstract

The glutamine antagonist DRP-104 blocks purine synthesis and combines with checkpoint inhibitors to promote antitumor immunity in KEAP1/NRF2-mutant lung cancers.

Original languageEnglish (US)
Article numbereado7808
JournalScience Advances
Volume10
Issue number13
DOIs
StatePublished - Mar 2024

ASJC Scopus subject areas

  • General

Fingerprint

Dive into the research topics of 'Glutamine antagonists may KEAP lung cancer in check'. Together they form a unique fingerprint.

Cite this